APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 323 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $235,848 | -84.8% | 6,200 | -63.5% | 0.00% | -66.7% |
| Q2 2023 | $1,548,700 | -70.3% | 17,000 | -78.5% | 0.00% | -72.7% |
| Q1 2023 | $5,210,114 | -47.0% | 78,989 | -58.4% | 0.01% | -31.2% |
| Q4 2022 | $9,829,037 | +86.5% | 190,080 | +146.4% | 0.02% | +100.0% |
| Q3 2022 | $5,269,000 | -36.6% | 77,153 | -58.0% | 0.01% | 0.0% |
| Q2 2022 | $8,309,000 | +9.0% | 183,763 | +22.5% | 0.01% | +100.0% |
| Q1 2022 | $7,623,000 | +39.2% | 150,010 | +29.5% | 0.00% | 0.0% |
| Q4 2021 | $5,477,000 | -6.3% | 115,836 | -34.7% | 0.00% | -20.0% |
| Q3 2021 | $5,844,000 | -69.8% | 177,344 | -42.0% | 0.01% | -72.2% |
| Q2 2021 | $19,333,000 | +2158.5% | 305,914 | +1067.9% | 0.02% | +1700.0% |
| Q2 2020 | $856,000 | -17.9% | 26,193 | -32.7% | 0.00% | 0.0% |
| Q1 2020 | $1,042,000 | +110.5% | 38,896 | +140.9% | 0.00% | – |
| Q4 2019 | $495,000 | +1275.0% | 16,144 | +861.0% | 0.00% | – |
| Q4 2017 | $36,000 | – | 1,680 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AJU IB Investment Co., Ltd. | 1,114,962 | $63,776,000 | 24.13% |
| Octagon Capital Advisors LP | 548,374 | $31,367,000 | 10.87% |
| Ghost Tree Capital, LLC | 325,000 | $18,590,000 | 4.14% |
| Burrage Capital Management LLC | 81,357 | $4,654,000 | 3.55% |
| Aufman Associates Inc | 53,642 | $3,068,000 | 2.75% |
| ACUTA CAPITAL PARTNERS, LLC | 167,054 | $9,555,000 | 2.60% |
| Cormorant Asset Management, LP | 1,866,108 | $106,741,000 | 2.54% |
| Tri Locum Partners LP | 121,409 | $6,945,000 | 2.52% |
| venBio Partners LLC | 490,471 | $28,055,000 | 2.48% |
| HHLR ADVISORS, LTD. | 5,028,289 | $287,618,000 | 2.29% |